Press Releases

Press Releases

DateTitle 
Nov 12, 2018
BURLINGAME, Calif. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present at the 27 th Annual
Nov 10, 2018
CPI-444 demonstrated prolonged survival in patients with refractory renal cell carcinoma both as a monotherapy and in combination with atezolizumab Novel adenosine gene signature biomarker associated with response to CPI-444 therapy CPI-006 early clinical data showed evidence of immune activation
Nov 05, 2018
Event will provide a review of new CPI-444 and CPI-006 data presented at SITC & ESMO BURLINGAME, Calif. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted
Nov 01, 2018
BURLINGAME, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the third quarter ended
Oct 22, 2018
Predictive biomarker can potentially identify patients most likely to benefit from CPI-444 and other therapies targeting the adenosine pathway BURLINGAME, Calif. , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on
Oct 04, 2018
BURLINGAME, Calif. , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present data from its lead programs,
Oct 03, 2018
As Combination, CPI-444 Showed Elimination of Tumors in 90% of Treated Mice and Restoration of Immune Response in Mice with Tumors Resistant to Therapy with anti-PD-1 and anti-CTLA-4 BURLINGAME, Calif. , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.
Sep 25, 2018
BURLINGAME, Calif. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present at the Cantor
Aug 02, 2018
BURLINGAME, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the second quarter ended
Jul 31, 2018
BURLINGAME, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present at the 2018 Wedbush
Jun 28, 2018
Research elucidated novel mechanisms of CPI-444 indicating broad effects on several checkpoints BURLINGAME, Calif. , June 28, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely
May 30, 2018
BURLINGAME, Calif. , May 30, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present at the Jefferies 2018
May 03, 2018

BURLINGAME, Calif. , May 03, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the first quarter ended March

Apr 26, 2018
Three-arm Trial Will Evaluate CPI-006 as Monotherapy, in Combination with CPI-444 Adenosine Antagonist and in Combination with Pembrolizumab BURLINGAME, Calif. , April 26, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the
Mar 12, 2018
BURLINGAME, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that precisely target crucial enzymes and proteins in the immune
Mar 06, 2018
BURLINGAME, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that the company will present at the Cowen and
Mar 01, 2018
BURLINGAME, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the fourth quarter and year
Feb 01, 2018
Company’s Investigational Small Molecule Inhibitor Demonstrates Safety and Activity in Canine Spontaneous T-Cell Lymphoma BURLINGAME, Calif. , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and